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Abstract
Objectives: To compare the dopaminergic neuronal imaging features of different subtypes of genetic Parkinson’s Disease.
Methods: A retrospective study of genetic Parkinson’s diseases cases in which DaTSCAN (123I-FP-CIT) had been performed.
Specific non-displaceable binding was calculated for bilateral caudate and putamen for each case. The right:left asymmetry
index and striatal asymmetry index was calculated.
Results: Scans were available from 37 cases of monogenetic Parkinson’s disease (7 glucocerebrosidase (GBA) mutations, 8
alpha-synuclein, 3 LRRK2, 7 PINK1, 12 Parkin). The asymmetry of radioligand uptake for Parkinson’s disease with GBA or LRRK2
mutations was greater than that for Parkinson’s disease with alpha synuclein, PINK1 or Parkin mutations.
Conclusions: The asymmetry of radioligand uptake in Parkinsons disease associated with GBA or LRRK2 mutations suggests
that interactions with additional genetic or environmental factors may be associated with dopaminergic neuronal loss.
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Introduction
Parkinson’s disease (PD) is the second most common neurode-
generative disorder worldwide with a prevalence of 1–2% in the
population aged over 65 years [1]. The vast majority of PD is late
onset, sporadic and of unknown aetiology. However, 5–10% of PD
cases are associated with mutations in a range of genes inherited in
an autosomal dominant, autosomal recessive or apparently
sporadic pattern [2]. The most common genetic risk factor for
PD is mutation of the glucocerebrosidase (GBA) gene, which encodes a
lysosomal enzyme deficient in the lysosomal storage disorder
Gaucher disease (GD) [1]. In sporadic PD between 5–30% of cases
have a heterozygous GBA mutation, with the highest frequency in
Ashkenazi Jews, while 8.4% of European autosomal dominant PD
families have GBA mutations [3]. The second most common
genetic cause of PD is the G2019S mutation of LRRK2, which
typically presents with late onset features resembling sporadic PD
[4]. The frequency of LRRK2 G2019S in sporadic PD in
Caucasians varies from 0.5–5% depending on population studied
[1,4]. Mutations of the SNCA gene, which encodes alpha synuclein,
the principle component of the Lewy body, cause early onset
autosomal dominant PD [5]. SNCA mutations are rare, accounting
for less than 0.5% of PD cases [1,5]. The penetrance for
development of PD varies greatly between these different genes;
being 15% by age 80 for GBA [12], around 80% by age 80 for
LRRK2 [4] and almost 100% for SNCA mutations [1,5]. This
suggests that mutations in GBA or LRRK2 are not sufficient by
themselves to cause symptomatic PDneurodegeneration and that
interactions between GBA or LRRK2 protein and other genetic or
environmental factors influence penetrance.
Autosomal recessive Juvenile Parkinson’s disease (ARJPD) is
clinically distinct from both sporadic PD and the genetic causes
outlined above [6]. Fifty percent of familial and 15% of sporadic
early onset PD (onset before 45 years old) is due to bi-allelic
mutations (i.e. homozygous or compound heterozygous) in the
Parkin gene [1,6]. Parkin disease differs from non-Parkin PD in that
early lower limb dystonia and bilateral motor Parkinsonian signs
are more common, non-motor symptoms are less severe and, in
general, there is an absence of Lewy bodies histologically [6,7,8].
PINK1 mutations are the second most common cause of early
onset PD, present in 2–4% of cases [9]. Clinical reports of PINK1
associated PD emphasise a slow disease progression, prominent
gait impairment and marked neuropsychiatric symptoms com-
pared to sporadic PD [9]. Mutations in DJ-1 are rare, accounting
for just 1% of early onset PD [1,6]. Bi-allelic mutations in PINK1,
Parkin and DJ-1 are highly penetrant for PD, suggesting that
interactions with additional genetic or environmental factors are
not required for neurodegeneration to occur in these genetic
subtypes of PD.
PD is diagnosed clinically based upon the Queens Square Brain
Bank criteria, with a positive predictive value of 90% for
neuropathological evidence of PD if these criteria are met [1].
In clinical practice imaging to detect pre-synaptic dopaminergic
neuronal dysfunction is performed to aid diagnosis when
Parkinsonian signs are present but clinical criteria for PD are
not fully met [10]. These imaging studies involve visualisation of
radioactive dopamine transporter (DAT) ligands (e.g. 123-I-FP-
CIT, 99m-Tc-TRODAT-1) or 18F-DOPA with positron emission
tomography (PET) or single photon emission computed tomogra-
phy (DAT-SPECT). DAT-SPECT and 18F-DOPA-PET have
been studied extensively in sporadic PD and ‘‘Parkinson’s plus’’
syndromes [10]. However, there are limited reports of dopami-
nergic neuronal imaging in genetic PD. We sought to examine the
hypothesis that mutations in GBA and LRRK2 would have
asymmetrical loss of radioligand, reflecting initially focal neuro-
degeneration due to interactions with additional endogenous or
exogenous pathogenic factors, whilst PD with bi-allelic PINK1 or
Parkin mutations would manifest more symmetrical radioligand
loss since mutations in these genes alone is sufficient to induce
neurodegeneration. To do this, we studied 123-I-FP-CIT
(DaTSCAN) appearances in what is to our knowledge the largest
series of genetic PD patients reported.
Materials and Methods
We formed a consortium of Movement Disorders and
Neurogenetics centres from Western Europe, South America
and Asia to identify a large series of monogenetic PD cases.
Mutations in GBA, SNCA, LRRK2, Parkin, or PINK1 were identified
by molecular genetic sequencing according to standard clinical
protocols. From amongst such patients individuals who had been
imaged with DaTSCAN as part of their initial clinical evaluation
were identified by retrospective chart review. Electronic copies of
each scan were collated for analysis at a single site (University
College London).
A region of interest (ROI) analysis was performed using Image J
(NIH, Bethesda, MD). Four ROIs were anatomically defined:
right and left caudate, right and left putamen. ROIs were
manually defined using the ellipse tool in Image J. To permit
calculation of background signal a region of occipital cortex was
designated as a 5th ROI. The outcome measure was the specific-
to-nondisplaceable binding ratio V3’’ (ROIstriatum – ROIoccipi-
tal/ROIoccipital) [11]. For each ROI, 4 transaxial slices were
analysed. Four slices showing the most intense radiotracer uptake
were selected for analysis from each case. For each case the
right:left asymmetry index (ASI, most severely affected ROI V3’’/
least severely affected ROI V3’’, e.g. ipsilateral caudate ROI V3’’/
contralateral caudate ROI V3’’) was calculated for caudate and
putamen [11]. The whole striatal asymmetry index was also
calculated (SASI: (ipsilateral-contralateral striatum V3’’)/((ipsila-
teral+contralateral striatumV3’’)/2)*100%), where the striatum
was defined as the caudate plus putamen value [9]. The ASI
calculates the ratio of ligand binding in the most severely affected
caudate or putamen compared to the least severely affected side, a
ratio of 1.0 indicates perfect symmetry while values of less than 1.0
indicate progressively worse asymmetry. This score enables
differentiation of whether asymmetry is predominantly due to loss
of caudate or putamen uptake. The SASI gives a summary
measure of asymmetry in the whole striatum, defined as uptake in
caudate plus putamen. Higher SASI values indicate greater
degrees of asymmetry. Images were analysed blind to the genetic
diagnosis by a single investigator (AM), apart from the SNCA scans
which were reported by SB.
Statistical analysis was performed with PASW 20.1 (version
20.1, IBM). Differences in median ASI and SASI between
genotypes were sought using the Mann-Whitney U-test. Signifi-
cance was taken at the 5% level (p = 0.05), with bonferroni
correction (i.e. p = 0.05/n where n = number of comparisons).
Demographic variables of patients were compared using one way
ANOVA and chi-squared test.
Ethics Statement
All participating institutions had research ethics board approv-
als for the project and written informed consent was taken as
appropriate. No participant had cognitive impairment which
meant they could not give informed consent. London: North West
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London Research Ethics Committee (REC number 10/H0720/
21). Spain: The Institutional Review Board (IRB) at the University
of Navarra, (Pamplona, Spain) approved the study. Brazil: Ethics
committee of Hospital Israelita Albert Einstein Taiwan: Research
Ethics committee C. Taiwan: National Taiwan University
Hospital. Italy: ethics committee of University of Naples Federico
II. Rotterdam: medical ethics committee of Erasmus MC
Rotterdam.
Results
Clinical and genetic characteristics of the 37 genetic PD patients
enrolled are given in Table 1. Table 2 summarises DaTSCAN
findings. Control DaTSCAN images were available from 12
individuals without neurological disease from the European
Nuclear Medicine Consortium (provided by Dr John Dickson,
Nuclear Medicine Department University College London Hos-
pital). All scans were performed according to standard clinical
protocols. All of the DaTSCANS utilised in the current study had
previously been reported as showing reduction of radioligand
binding compatible with PD. Ethical approvals were obtained at
each centre and written informed consent taken as required. The
PINK1 [9], heterozygous GBA mutation associated PD [12],
Brazilian Parkin and LRRK2 patients [13], SNCA cases [14] and
Italian Parkin cases [15] have been reported previously.
The age at assessment (one way ANOVA, p.0,05), sex and
proportion of patients taking levo-dopa for each genetic subgroup
did not differ significantly (both chi-squared test, p.0.05)
(Table 1). The disease duration did not differ between groups
(one way ANOVA, F = 2.3, p = 0.076). The UPDRS part III
scores for the PINK1 group were significantly lower than the other
genetic subgroups (p,0.05 for all comparisons with Bonferroni
correction). The control group were all of Western European
ancestry but did not differ significantly from the PD group for age
(52+/212 years, p.0.05) or sex (7/12 male, chi-squared test
p.0.05).
The caudate ASI for the PD cases with GBA mutations (Mann-
Whitney U-test, median ASI 0.42 [0.33–0.56], p,0.001) was
different to the control value of 0.92 (interquartile range 0.89–
0.92) (Table 1 and Figure 1a). The caudate asymmetry indices for
PD with bi-allelic Parkin (median 0.88 [0.72–0.93]. p = 0.19),
PINK-1 (median 1.0 [0.9–1.13], p = 0.065), LRRK2 G2019S
(median 1.0 [0.6–1.1], p = 0.38), or SNCA (median 1.02 [0.9–
1.13], p = 0.91) did not differ from the control value. This indicates
an asymmetric reduction of radioligand uptake in the caudate of
PD associated with GBA mutations with a relatively symmetrical
reduction in ligand uptake in the caudate of PINK1, Parkin, LRRK2
G2019S and SNCA mutation associated PD.
The putamen ASI for PD cases with GBA mutations (median
0.18 [0.08–0.33], p,0.001) and LRRK2 (median 0.52 [0.13–0.5],
p,0.001) differed significantly from the control value (median
0.89 [0.82–0.96])(Figure 1b). The putamen ASI for bi-allelic Parkin
(median 0.69 [0.2–1.0], p = 0.2), PINK1 (median 1.05 [0.9–1.4],
p = 0.14) and SNCA (median 1.05 [0.92–1.22], p = 0.30) mutation
associated PD did not differ from control values (median 0.89
[0.82–0.86]). This indicates an asymmetric reduction of radioli-
gand uptake in the putamen of PD associated with GBA and
LRRK2 mutations with a relatively symmetrical reduction in ligand
Table 1. Clinical, genetic and demographic characteristics of patient cohort.
GBA PARKIN PINK1 LRRK2 SNCA
Male 7/7(100%) 9/12 (75%) 5/7(55%) 3/3 (100%) 5/8 (62.5%)
Age at scan
(years)
50+/213 44+/214 42+/217 51.5+/219 47.1+/27.5
Disease duration
(years)
7+/24 14.5+/210 12.3+/211 5.5+/3 7.4+/22
Mutation N370S/L444P (1/7),
N370S (1/7),
L444P (1/7),
IVS2+1G.A(1/7),
E326K(1/7),
T369M (1/7),
R496H (1/7).
Del exon 3/del exon 3 (1/12),
Del exon 3–4/del exon 3–4 (1/12),
Del exon 3/del exon 2–3 (1/12),
Del exon 2/del exon 2–4 (1/12),
C820T/del exon 2 (1/12),
G96C/C1305T (1/12),
R42P/R42P (3/12),
G429EfsX5/G429EfsX5 (3/12).
1573insTTAG/1573insTTAG (1/7),
1488+1G.A/1488+1G.A (1/7),
1488+1G.A/1252_1488del (5/7)
G2019S (2/3)
R1441C (1/3)
G209A (8/8)
L-DOPA use 4/7 (57%) 8/12 (66%) 5/9 (55%) 2/3 (66%) 8/8 (100%)
UPDRS III 29.8+25 28.2+/212.7 12.8+/26 30+/213 36.2+/214
doi:10.1371/journal.pone.0069190.t001
Table 2. Asymmetry indices for each subtype of genetic Parkinson’s disease.
GBA LRRK2 Parkin PINK1 SNCA
CASI 0.42* [0.33–0.56] 1.0 [0.6–1.1] 0.88 [0.7–0.93] 1.0 [0.89–1.13] 1.02 [0.9–1.13]
ASI 0.18* [0.08 0.33] 0.49* [0.13–0.5] 0.69 [0.2–1.0] 1.05 [0.9–1.4] 1.05 [0.92–1.22]
SASI 80+/25.1 44+/211.5 32+/26 13.6+/24.4 13.4+/211
Key: CASI, PASI = right/left asymmetry index quoted as median and interquartile range for caudate and putamen, SASI = striatal asymmetry index quoted as mean and
standard error.
* = significantly different than ASI from control (Mann-Whitney u-test).
doi:10.1371/journal.pone.0069190.t002
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uptake in the putamen of PINK1, Parkin and SNCA mutation
associated PD.
To further explore these findings, the whole striatum asymmetry
index (SASI) was calculated (Figure 2). Mann-Whitney U testing
with bonferroni correction demonstrated that the SASI for PD-
GBA (mean 80.5+/25.1, p = 0.001) and LRRK2 (44.0+/211.5,
p = 0.009) was significantly higher than controls (mean 8.3+/
22.7). The SASI did not differ significantly between PINK1,
Parkin, SNCA and controls (p.0.05 for all). Representative
DaTSCANS are shown in Figure 3.
Discussion
Here we report what is, to our knowledge, the largest series
directly comparing the dopaminergic imaging features of the most
important causes of genetic PD. The key finding is a difference in
the pattern of imaging abnormality between the separate
mutations. GBA and LRRK2 mutations are associated with
relatively asymmetric striatal dopaminergic neuronal loss, while
Parkin, PINK1 and SNCA mutation patients have relatively
symmetrical loss. We believe that this difference in the pattern
of striatal dopaminergic loss reflects separate influences of the
respective mutations on the aetiopathogenesis of PD.
The results of our comparison of dopaminergic neuronal
imaging features are in keeping with previous reports of imaging
of single PD genotypes. There are 2 reports of DAT-SPECT in
Gaucher disease patients with PD or PD patients with heterozy-
gous GBA mutations [16,17]. Though not formally quantified,
inspection of the published images reveals clear asymmetry of
radioligand uptake affecting the striatum. Here we confirm
asymmetric loss of dopaminergic neurons in PD associated with
heterozygous GBA mutations.
Multiple studies of Parkin mutation associated PD using both
DAT-SPECT and 18-F-DOPA-PET clearly describe a symmet-
rical reduction in striatal radioligand uptake [18–20]. The
DAT-SPECT and 18-F-DOPA-PET features of PD patients
with bi-allelic Parkin mutations reported herein is entirely in
keeping with this. DAT-SPECT in PINK1 linked PD is usually
Figure 1. Caudate and putament asymmetry index for subtypes of genetic Parkinson’s disease. 1a. Boxplot of caudate asymmetry index
for each genotype. Median caudate asymmetry is signficantly different for GBA compared to control. 1b. Boxplot of putamen asymmetry index for
each genotype. Median putamen asymmetry is significantly different for GBA and LRRK2 groups compared to control.
doi:10.1371/journal.pone.0069190.g001
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described as symmetrical but some reports state that it is
asymmetrical in a pattern reminiscent of sporadic PD [9,21–22].
As previously described we found that the LRRK2 mutation
carriers with PD had relatively asymmetric loss of radioligand
uptake on DAT-SPECT [23,24]. The SNCA mutation PD cases
reported here had symmetric reduction of ligand binding. This
is in keeping with reports of 18F-DOPA in PD with the A53T
mutation which demonstrated relatively symmetrical loss of
radioligand uptake [25], however, reports of SNCA multiplica-
tion associated PD describe an asymmetrical pattern of reduced
tracer uptake [26,27].
The currently available data on the pathogenetic mechanisms
underlying monogenetic PD may help to explain the differences
in symmetry of radioligand uptake between genotypes [28,29].
Intuitively, it might be expected that a genetic cause of PD
present from birth and presumably expressed symmetrically in
expressing tissues, would result in symmetric clinical features
and striatal imaging loss. In agreement with this PINK1 and
Parkin mutations are generally associated with early onset,
relatively symmetrical parkinsonism [1,6]. Both PINK1 and
Parkin proteins are proposed to play a role in clearing damaged
mitochondria, and there is evidence that loss of function of
these proteins is associated with mitochondrial dysfunction
[30,31]. The diffuse and symmetrical loss of dopaminergic
neurons reported by us, and others [18,20–22], may reflect
widespread dysfunction and degeneration of striatal dopaminer-
gic neurons due to a general predisposition to neuronal
mitochondrial dysfunction in PINK1 and Parkin mutation
associated PD. SNCA mutations are proposed to act chiefly by
facilitating Lewy body formation [32]. The symmetrical loss of
dopaminergic neurons on DAT-SPECT reported herein may
thus reflect a generalised, homogeneous increase in Lewy body
formation in the striatum since the mutation is present in every
cell.
By contrast, GBA and LRRK2 mutations are most commonly
associated with a phenotype and age of onset that closely
resembles late onset sporadic PD [1,4,12]. This suggests that
these mutant proteins may interact with additional pathogenetic
process, either genetic or environmental, predisposing to age
related PD. For example in PD with mono- or bi-allelic GBA
mutations there is reduction or loss of glucocerebrosidase
enzyme activity in the brain, most severe in the substantia nigra
[35], associated with elevated alpha-synuclein deposition as
measured by Western blot [35]. Both cell biology and mouse
studies indicate that inhibition of glucocerebrosidase activity is
associated with elevated alpha-synuclein accumulation [33]. The
asymmetric loss of dopaminergic neurons observed in PD with
GBA mutations may thus reflect a stochastic element whereby
there is a focal loss of glucocerebrosidase activity below a
critical level eventually resulting in an initially focal accumula-
tion of alpha-synuclein and Lewy body formation. There is
evidence from human brain and cell models that alpha-
synuclein accumulation results in inhibition of glucocerebrosi-
dase, thus causing a ‘‘feed forward’’ mechanism which could
contribute to the spread of pathology and neurodegeneration
[33,34]. We recently described loss of glucocerebrosidase activity
associated with alpha-synuclein accumulation in brain tissue
from PD without GBA mutations [33]. This suggests that a
similar mechanism may operate in sporadic PD and may
account partly for the similarities in dopaminergic neuronal
imaging and clinical phenotype between sporadic PD and PD
associated with GBA mutations. We hypothesised that GBA
mutations accelerated or enhanced pathogenetic mechanisms
associated with the cause of sporadic PD [33] and the present
imaging results support this. Mutant LRRK2 protein has
recently been shown to inhibit chaperone mediated autophagy.
In theory this could result in focal loss of lysosomal degradation
of alpha-synuclein in the brain of LRRK2 G2019S mutation
carriers, causing initially asymmetrical Lewy body deposition
and loss of dopaminergic neurons [35].
Recessive forms of genetic PD (Parkin, PINK1) generally
demonstrate relatively symmetric loss of radioligand uptake in
Figure 2. Striatal asymmetry index by genotype. The striatal asymmetry index was significantly higher for the GBA and LRRK2 genotypes
(p,0.001). Graph shows mean SASI +/21 standard error.
doi:10.1371/journal.pone.0069190.g002
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the striatum. PD associated with heterozygous mutations in GBA
or LRRK2 G2019S, which can present with dominant or
apparently sporadic PD, produces a relatively asymmetric
pattern of loss of radioligand uptake. In clinical practice
asymmetric loss of radioligand binding should not exclude a
genetic aetiology for PD while relatively symmetric decrease
should raise suspicion of a monogenetic form of PD. The
asymmetric loss of dopaminergic neurons in GBA and LRRK2
associated PD supports the hypothesis of additional interactions
with genetic or environmental factors leading to age related
neurodegeneration in these genotypes.
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